Половая верификация в спорте: история и современные вопросы.

None

Sex verification in sports (also known as gender verification, or loosely as gender determination or a sex test) occurs because eligibility of athletes to compete is restricted whenever sporting events are limited to a single sex, which is generally the case, as well as when events are limited to mixed sex teams of defined composition (e. g., most pairs events). Practice has varied tremendously over time, across borders and by competitive level. Issues have arisen multiple times in the Olympic games and other high profile sporting competitions, for example allegations that certain male athletes attempted to compete as women or that certain female athletes had intersex conditions perceived to give unfair advantage. The topic of sex verification is related to the more recent question of how to treat transgender people in sports. Sex verification is not typically conducted on athletes competing in the male category because there is generally no perceived competitive advantage for a female or intersex athlete to compete in male categories. Sex verification in sports began in the 1940s with "femininity certificates" provided by a physician. It subsequently evolved into visual inspections, physical examinations, chromosome testing, and later testosterone level testing. These tests were all designed to ensure that athletes were only allowed to compete as their sex, but mostly resulted in the exclusion of intersex athletes from female sports. Mandatory sex verification testing was fuelled by anxieties surrounding the "unfemininity" of some female athletes, as more participated in masculine events (e. g., track and field). The first mandatory sex test issued by the International Association of Athletics Federations (IAAF), the world's track and field governing body, for woman athletes was in July 1950 in the month before the European Championships in Belgium. All athletes were tested in their own countries. The IAAF instituted sex testing at the actual games, starting at the 1966 European Athletics Championships in response to suspicion that several of the best women athletes from the Soviet Union and Eastern Europe were actually men. At the Olympics, testing was introduced in 1968.

United States Olympic Committee president Avery Brundage requested, during or shortly after the 1936 Summer Olympics in Berlin, that a system be established to examine female athletes. According to a Time magazine article about intersex people, Brundage felt the need to clarify "sex ambiguities" after observing the performance of Czechoslovak runner and jumper Zdeňka Koubková and English shotputter and javelin thrower Mary Edith Louise Weston. Both individuals later had gender reassignment surgery and legally changed their names, to Zdeněk Koubek and Mark Weston, respectively. Sex verification tests began in 1950 with the IAAF, using physical examinations. "Sex segregation and verification are mutually interdependent because, if there were no claims or basis for having separate male and female sporting events, there would be no need for sex verification testing." Initially, women athletes "were asked to parade nude before a panel of doctors". and many athletes reported feeling humiliated by these procedures. The International Olympic Committee (IOC) never adopted these methods.

From 1958 to 1992, all female athletes underwent mandatory sex verification tests before taking part in any IAAF or IOC event. Barr body tests were conducted by taking samples from inside the cheek to find evidence of XX chromosomes, supposedly indicating the athlete was female. Martínez Patiño was told to retire discreetly due to her results, which was commonplace among athletes who failed gender verification tests. However, she refused to retire, leading to immense public scrutiny. Finnish geneticist Albert de la Chapelle worked alongside Martínez Patiño to appeal the decision to the IAAF. De la Chapelle protested sex testing in sports for years, arguing that the Barr body test incorrectly identified intersex women. Furthermore, he pointed out that the finding of the abnormal sex chromatin and exclusion of these athletes from women's sporting events violated their rights and caused psychological damage. With de la Chapelle's support, the IAAF reinstated Martínez Patiño in 1988. Martínez Patiño's case, and later advocacy, led to the elimination of chromosomal sex verification tests. This method of testing was later abolished, as it was shown to be inconclusive in identifying maleness. The International Association of Athletics Federations ceased sex screening for all athletes in 1992, but retained the option of assessing the sex of a participant should suspicions arise. As well, in 1992, the IOC continued compulsory sex verification, but switched from the Barr body test to a Polymerase Chain Reaction (PCR) test to look for "male related genetic material" through DNA samples collected from a buccal swab. This test was still subject to criticism and several medical associations opposed gender verification by the late 1990s. A resolution was passed at the 1996 International Olympic Committee (IOC) World Conference on Women and Health "to discontinue the current process of gender verification during the Olympic Games". The International Olympic Committee's board voted to discontinue the practice in June 1999. Chromosome testing was last performed at the Atlanta Olympic Games in 1996.

In 2006, the IAAF published a new Policy on Gender Verification. This allowed the organization to subject athletes to medical examinations by gynaecologists, endocrinologists, psychologists, internal medicine specialists, and experts on gender/transgender issues suspicions arose of the athlete's gender. The IAAF clarified the sex determinations would not be made on the sole basis of laboratory based results. Athletes were provided with the option to undergo medical and surgical procedures to compete if they had failed the gender verification testing. Furthermore, the 2006 Policy listed conditions that would not provide advantages over other females, thus allowing the athlete to compete. These included: Androgen Insensitivity Syndrome (AIS), Gonadal dysgenesis, Turner's Syndrome, congenital adrenal hyperplasia, androgen producing tumours, and polycystic ovary syndrome (PCOS). In the wake of the Semenya case, testosterone testing was introduced to identify cases where testosterone levels were elevated above a particular level, termed hyperandrogenism, with national Olympics committees tasked by the IOC to "actively investigate any perceived deviation in sex characteristics". In 2011, the IAAF released new protocols related to testosterone and hormone testing. The protocols rejected the terms "sex testing" and "gender verification" and placed emphasized importance on testosterone levels, as certain athletes would not be eligible to compete in the female category due to hormonal characteristics. The protocols claimed that hormone levels indicated the differences in athletic performance between men and women. In association football, FIFA's current gender verification policy dates to 30 May 2011. In June 2012, in advance of the 2012 Summer Olympics, the IOC released IOC Regulations on Female Hyperandrogenism to address these cases. It includes the statement:"Nothing in these Regulations is intended to make any determination of sex. Instead, these Regulations are designed to identify circumstances in which a particular athlete will not be eligible (by reason of hormonal characteristics) to participate in 2012 Olympic Games (OG) Competitions in the female category. In the event that the athlete has been declared ineligible to compete in the female category, the athlete may be eligible to compete as a male athlete, if the athlete qualifies for the male event of the sport. "Policies on hyperandrogenism were suspended following the case of Dutee Chand v. Athletics Federation of India (AFI) & The International Association of Athletics Federations, in the Court of Arbitration for Sport, decided in July 2015. Chand had been dropped from the 2014 Commonwealth Games at the last minute after the Athletic Federation of India stated that hyperandrogenism made her ineligible to compete as a female athlete. The ruling found that there was insufficient evidence that testosterone increased female athletic performance. In doing so the court immediately suspended the practice of hyperandrogenism regulation used by the IAAF and declared it void unless the organization could present better evidence by July 2017. A study published in 2017 by Stéphane Bermon and Pierre Yves Garnier analyzed 2,127 performances and hormone concentrations in male and female elite track and field athletes during the 2011 and 2013 Track and Field World Championships. When compared with women with lower levels of the hormone free testosterone (fT), women with the highest fT levels performed significantly better in the 400 m, 400 m hurdles, 800 m, hammer throw, and pole vault with margins of 2.73%, 2.78%, 1.78%, 4.53%, and 2.94%, respectively. Such a pattern was not found in any of the male athletic events. The study concluded that female athletes with high testosterone levels have a significant competitive advantage over those with low fT in 400 m, 400 m hurdles, 800 m, hammer throw, and pole vault. Scholars question whether any advantage should be considered "unfair" if it occurs naturally and outside the control of the athlete. For example, elite athletes have greater aerobic capacity and endurance in comparison to the general population. Furthermore, these cases have elicited criticism of the elite sporting system by showing clear vulnerability of women athletes to unnecessary medical interventions under duress, applied even though there was no evidence of cheating and no evidence of athletic advantage. Moreover, the requirement to lower testosterone levels can have adverse impacts on athlete's health, as side effects may include: excessive thirst, urination and electrolyte imbalances, disruption of carbohydrate metabolism, headache, fatigue, nausea, hot flushes, and liver toxicity. Other commentators question the causal connection between testosterone and athletic capability, as some women who have high testosterone are prone to biological characteristics, such as obesity and short stature, that adversely impact athletic ability. As well, other factors, such as mitochondrial variations, acromegaly, a complete and balanced diet, and access to high level training at an early age, are said to be as relevant as testosterone, but are not considered. as humiliating, unnecessary, unethical, and discriminatory. They recommend that athletes be able to compete in accordance with their legal gender. In November 2015, the IOC held a meeting to address both its hyperandrogenism and transgender policies. In regards to hyperandrogenism in female athletes, the IOC encouraged reinstatement of the IAAF policies suspended by the Court of Arbitration for Sport. It also repeated an earlier policy statement that, to "avoid discrimination, if not eligible for female competition the athlete should be eligible to compete in male competition". In February 2016, it was made known that the IOC would not introduce its own policies that would impose a maximum testosterone level for the 2016 Summer Olympics. In April 2016, the United Nations Special Rapporteur on health, Dainius Pūras, criticized current and historic sex verification policies, describing how "a number of athletes have undergone gonadectomy (removal of reproductive organs) and partial cliteroidectomy in the absence of symptoms or health issues warranting those procedures".

Women with higher levels of androgen (particularly testosterone) are often considered to have a competitive advantage over other women since women statistically have lower levels than men. This difference in androgen levels is the reason many sports requiring athletes compete only among their own sex. However, others argue that expecting women athletes with naturally higher levels of testosterone to lower these levels by medical/pharmaceutical methods completely contradicts the purpose of doping regulations, which require athletes to not take any substances that their bodies do not generate naturally. In January 2010 in Miami, instead of succeeding in improving the policies specifying whether an athlete should participate as a woman or a male, medical professionals experienced ambiguity in regards to these policies. Alice Dreger states it is risky to publicly reveal that an athlete is no longer allowed to compete as a woman without first informing the athlete. For example, Caster Semenya found out through public media that the tests she had taken were meant to determine whether she is female or male. Another athlete, Santhi Soundarjan, had a suicide attempt subsequent to failing the test for determining her gender and being stripped of her 2016 Asian Games medal.

Sex verification is not conducted on athletes competing in the male category, and little data are available on their chromosomes or hormone profiles. However, a post competition study of 693 elite athletes by Healy et al., published in 2014, found significant differences along many variables. The authors found that:

blockquote|16.5% of men had low testosterone levels, whereas 13.7% of women had high levels with complete overlap between the sexes. The study authors also stated that average lean body mass differences might account for performance differences between sexes.